Samil Pharmaceutical Unregistered Executive Kim Young-dae Acquires 1,000 Shares via Open Market Purchase, Holding 0.01% Stake

The filer Kim Young-dae, an unregistered executive of Samil Pharmaceutical, acquired 1,000 common shares on June 5, 2026 at 7,040 KRW per share through open market purchase.
This transaction brings his total holdings to 1,000 shares, representing a mere 0.01% of the total outstanding shares of 21,691,811.
The impact on stock price and governance is negligible due to the tiny stake; insider buying signal is weak.
[AI Summary]This routine insider purchase report has no material impact on company valuation or financial position. The acquisition size is too small to affect shareholder value.